JP2020511123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511123A5 JP2020511123A5 JP2019545292A JP2019545292A JP2020511123A5 JP 2020511123 A5 JP2020511123 A5 JP 2020511123A5 JP 2019545292 A JP2019545292 A JP 2019545292A JP 2019545292 A JP2019545292 A JP 2019545292A JP 2020511123 A5 JP2020511123 A5 JP 2020511123A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 78
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 claims description 39
- 102100021596 Interleukin-31 Human genes 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 15
- 241000282326 Felis catus Species 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 241000283073 Equus caballus Species 0.000 claims description 12
- 241000282465 Canis Species 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 10
- 241000282472 Canis lupus familiaris Species 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229960002885 histidine Drugs 0.000 claims description 7
- 238000012575 bio-layer interferometry Methods 0.000 claims description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960002216 methylparaben Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000003119 immunoblot Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 230000009131 signaling function Effects 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- -1 CD11α Proteins 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010027654 Allergic conditions Diseases 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108010041012 Integrin alpha4 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 108010065637 Interleukin-23 Proteins 0.000 claims description 2
- 102000013264 Interleukin-23 Human genes 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 239000012828 PI3K inhibitor Substances 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 102000045345 human IL31 Human genes 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007919 intrasynovial administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 241000283086 Equidae Species 0.000 claims 2
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076588A JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
| JP2025087766A JP2025138636A (ja) | 2017-02-24 | 2025-05-27 | 獣医用抗ｉｌ－３１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463543P | 2017-02-24 | 2017-02-24 | |
| US62/463,543 | 2017-02-24 | ||
| USPCT/US2017/023788 | 2017-03-23 | ||
| PCT/US2017/023788 WO2018156180A1 (en) | 2017-02-24 | 2017-03-23 | Anti-il31 antibodies for veterinary use |
| PCT/US2018/017623 WO2018156367A1 (en) | 2017-02-24 | 2018-02-09 | Anti-il31 antibodies for veterinary use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076588A Division JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511123A JP2020511123A (ja) | 2020-04-16 |
| JP2020511123A5 true JP2020511123A5 (https=) | 2021-03-18 |
| JP7277370B2 JP7277370B2 (ja) | 2023-05-18 |
Family
ID=63245488
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545292A Active JP7277370B2 (ja) | 2017-02-24 | 2018-02-09 | 獣医用抗ｉｌ－３１抗体 |
| JP2023076588A Active JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
| JP2025087766A Pending JP2025138636A (ja) | 2017-02-24 | 2025-05-27 | 獣医用抗ｉｌ－３１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076588A Active JP7716441B2 (ja) | 2017-02-24 | 2023-05-08 | 獣医用抗ｉｌ－３１抗体 |
| JP2025087766A Pending JP2025138636A (ja) | 2017-02-24 | 2025-05-27 | 獣医用抗ｉｌ－３１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US10093731B2 (https=) |
| EP (1) | EP3585429A4 (https=) |
| JP (3) | JP7277370B2 (https=) |
| KR (2) | KR102942127B1 (https=) |
| CN (2) | CN110769851B (https=) |
| AU (2) | AU2018224711B2 (https=) |
| BR (1) | BR112019017308A2 (https=) |
| CA (1) | CA3053525A1 (https=) |
| MA (1) | MA47609A (https=) |
| MX (1) | MX2024012304A (https=) |
| WO (1) | WO2018156180A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| WO2018162577A1 (en) * | 2017-03-07 | 2018-09-13 | Universität Zürich | Treatment of pruritus in horses |
| US11433139B2 (en) | 2018-03-16 | 2022-09-06 | Zoetis Services Llc | Peptide vaccines against interleukin-31 |
| CN113454117B (zh) * | 2018-12-19 | 2025-07-04 | 宾夕法尼亚大学董事会 | Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途 |
| BR112022002771A2 (pt) * | 2019-08-29 | 2022-08-09 | Kindred Biosciences Inc | Anticorpos anti-il31 para uso veterinário |
| CN121108343A (zh) | 2019-12-20 | 2025-12-12 | 英特维特国际股份有限公司 | 犬白介素-4受体α抗体 |
| MX2022007676A (es) * | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Anticuerpos caninizados biespecificos para tratar dermatitis atopica. |
| IL296276A (en) * | 2020-03-10 | 2022-11-01 | Tiziana Life Sciences Plc | Compositions of il-6/il-6r antibodies and methods of use thereof |
| MX2022012793A (es) * | 2020-04-17 | 2022-11-07 | Zoetis Services Llc | Variantes de anticuerpos felinos. |
| CN115996949A (zh) * | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| KR20230005875A (ko) * | 2020-04-22 | 2023-01-10 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학 용도를 위한 장시간-작용성 항-il31 항체 |
| KR20230038522A (ko) | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| JP2023545182A (ja) | 2020-10-15 | 2023-10-26 | インターベット インターナショナル ベー． フェー． | イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体 |
| WO2022109403A1 (en) * | 2020-11-23 | 2022-05-27 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| WO2022178201A1 (en) * | 2021-02-22 | 2022-08-25 | Zoetis Services Llc | Horse il-31 induced pruritus model |
| JP2024532158A (ja) | 2021-08-20 | 2024-09-05 | インターベット インターナショナル ベー． フェー． | アトピー性皮膚炎を治療するためのホモ二量体融合タンパク質 |
| MX2024007090A (es) | 2021-12-16 | 2024-08-22 | Intervet Int Bv | Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino. |
| US20240209096A1 (en) | 2022-12-27 | 2024-06-27 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2024145280A2 (en) | 2022-12-27 | 2024-07-04 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| AU2024210302A1 (en) | 2023-01-20 | 2025-09-04 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
| JP2026508149A (ja) | 2023-02-13 | 2026-03-10 | インターベット インターナショナル ベー． フェー． | イヌｉｌ－１３に対するイヌ抗体 |
| EP4665756A1 (en) | 2023-02-13 | 2025-12-24 | Intervet International B.V. | Canine antibodies to canine il-4 |
| CN120865401A (zh) * | 2023-11-27 | 2025-10-31 | 宁波贝安生物科技有限公司 | 抗il-31的抗体及其用途 |
| CN118667001B (zh) * | 2024-07-16 | 2025-05-06 | 华中农业大学 | 一种抗犬il-31的单克隆抗体及其应用 |
| CN120209126B (zh) * | 2025-05-28 | 2025-09-16 | 中国医学科学院医学生物学研究所 | 人偏肺病毒单克隆抗体及其应用 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片 |
| US5820858A (en) | 1993-05-28 | 1998-10-13 | The Scripps Research Institute | Methods and compositions for inhibiting CD14 mediated cell activation |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE402192T1 (de) | 2000-03-03 | 2008-08-15 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| US7261890B2 (en) | 2001-12-21 | 2007-08-28 | Idexx Laboratories, Inc. | Methods for using canine immunoglobulin variable domains and caninized antibodies |
| DK1961811T3 (da) | 2002-01-18 | 2010-11-08 | Zymogenetics Inc | Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet |
| WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| JP2008528039A (ja) | 2005-01-28 | 2008-07-31 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−３１の均質調製物 |
| EP1858924A1 (en) | 2005-02-14 | 2007-11-28 | ZymoGenetics, Inc. | Methods of treating skin disorders using an il-31ra antagonist |
| WO2006088955A2 (en) | 2005-02-14 | 2006-08-24 | Zymogenetics, Inc. | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| CA2601400A1 (en) | 2005-03-19 | 2006-09-28 | Medical Research Council | Improvements in or relating to treatment and prevention of viral infections |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| US8101183B2 (en) | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
| KR101443050B1 (ko) | 2005-05-06 | 2014-09-22 | 지모제넥틱스, 인코포레이티드 | Ｉｌ-31 단클론성 항체 및 사용법 |
| RU2444528C2 (ru) | 2005-05-06 | 2012-03-10 | Займоджинетикс, Инк. | Моноклональные антитела против il-31 и способы применения |
| US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
| CN1896229A (zh) * | 2005-06-29 | 2007-01-17 | 北京天广实生物技术有限公司 | 一种新型抗cd20嵌合抗体的制备及其用途 |
| CN101291692A (zh) * | 2005-10-21 | 2008-10-22 | 默克制药公司 | 抗addl单克隆抗体及其应用 |
| EP2749571A3 (en) | 2006-01-10 | 2014-08-13 | ZymoGenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| ES2548714T3 (es) | 2006-09-01 | 2015-10-20 | Zymogenetics, Inc. | Anticuerpos monoclonales IL-31 y procedimientos de uso |
| JP2010502224A (ja) | 2006-09-08 | 2010-01-28 | アボット・ラボラトリーズ | インターロイキン１３結合タンパク質 |
| PL2829551T3 (pl) | 2006-10-19 | 2018-04-30 | Csl Limited | Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13 |
| JP2010515755A (ja) | 2007-01-10 | 2010-05-13 | ザイモジェネティクス， インコーポレイテッド | 気道過敏および喘息を処置するためのｉｌ−３１の使用法 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| ME03057B (me) | 2007-12-07 | 2019-01-20 | Zymogenetics Inc | Molekuli humanizovanih antitela specifični za il-31 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| KR101335843B1 (ko) | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-ｄ]피리미딘 화합물 |
| EP2331579B1 (en) | 2008-09-04 | 2017-07-05 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| HUE035700T2 (en) | 2008-11-07 | 2018-05-28 | Galaxy Biotech Llc | Monoclonal antibodies to Fibroblast Growth Factor receptor 2 |
| WO2011065935A1 (en) | 2009-11-24 | 2011-06-03 | Cornell University | Methods for monoclonal antibody production |
| US20110287454A1 (en) | 2008-11-25 | 2011-11-24 | Cornell University | Methods for monoclonal antibody production |
| AU2013203075A1 (en) * | 2008-11-28 | 2013-05-02 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| US20110165063A1 (en) | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| RU2012101995A (ru) | 2009-06-22 | 2013-07-27 | Пептселл Лимитед | Фармацевтический агент |
| BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| AR081246A1 (es) | 2010-05-14 | 2012-07-18 | Abbott Lab | Proteinas de union a il-1 |
| TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| US9255925B2 (en) | 2010-10-20 | 2016-02-09 | Medical Diagnostic Laboratories, Llc | ELISA detection of urine DEK to predict and diagnose bladder cancer in humans |
| TWI452136B (zh) | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| TW201307388A (zh) | 2010-12-21 | 2013-02-16 | Abbott Lab | Ｉｌ－１結合蛋白 |
| WO2012147713A1 (ja) | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体 |
| AR086250A1 (es) | 2011-05-05 | 2013-11-27 | Hoffmann La Roche | Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo |
| GB2504887B (en) | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-Nerve growth factor antibodies and methods of preparing and using the same |
| JP2014516960A (ja) | 2011-05-19 | 2014-07-17 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 抗ヒトｈｅｒ３抗体及びその使用 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EP2970497B1 (en) | 2013-03-15 | 2017-10-25 | Bayer HealthCare LLC | Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics |
| EP2968454B1 (en) | 2013-03-15 | 2019-02-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| EP3003350B1 (en) | 2013-05-27 | 2018-02-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Targeted modulation of macrophages |
| HUE056580T2 (hu) | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| TW201537175A (zh) | 2013-06-28 | 2015-10-01 | Chugai Pharmaceutical Co Ltd | 預測罹患具皮膚搔癢之疾病的患者對ｉｌ－３１拮抗劑之治療的反應之方法 |
| WO2015002985A2 (en) | 2013-07-01 | 2015-01-08 | University Of Maryland | Fc coupled compositions and methods of their use |
| WO2015042596A1 (en) * | 2013-09-23 | 2015-03-26 | Kindred Biosciences, Inc | Treatment of atopic dermatitis in non-human animals |
| WO2015067755A2 (en) | 2013-11-07 | 2015-05-14 | Novo Nordisk A/S | Novel methods and antibodies for treating coagulapathy |
| WO2015086830A1 (en) | 2013-12-13 | 2015-06-18 | Delenex Therapeutics Ag | Skin penetrating polypeptides |
| CN103965357B (zh) | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| WO2016119023A1 (en) | 2015-01-29 | 2016-08-04 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
| CN104710528B (zh) * | 2015-03-13 | 2019-02-15 | 西北农林科技大学 | 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用 |
| JP5954916B1 (ja) | 2015-04-14 | 2016-07-20 | 中外製薬株式会社 | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| WO2015151079A2 (en) | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| WO2017025698A1 (en) | 2015-08-11 | 2017-02-16 | Queen Mary University Of London | Bispecific, cleavable antibodies |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| BR112018070097A2 (pt) * | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| KR20230119259A (ko) | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
| BR112018071465A2 (pt) | 2016-04-20 | 2019-02-05 | Hangzhou Dac Biotech Co Ltd | derivados de toxinas de amanita e sua conjugação a uma molécula de ligação celular |
| US20200181258A1 (en) | 2016-10-17 | 2020-06-11 | Vetoquinol Sa | Modified antibody constant region |
| KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2018156367A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| KR20210122319A (ko) | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| SG11201909160WA (en) | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| JP7657548B2 (ja) | 2017-04-21 | 2025-04-07 | エランコ・ユーエス・インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| EP3483180A1 (en) | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| MX2020006105A (es) | 2017-12-11 | 2020-11-09 | Ubi Ip Holdings | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. |
| EP3621652A4 (en) | 2017-12-31 | 2021-01-13 | Hangzhou DAC Biotech Co, Ltd | CONJUGATE OF ANALOGUE OF TUBULYSIN WITH BRANCHED LINKS |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| WO2019183449A1 (en) | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for allergic disorders |
| KR20260046525A (ko) | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| EA202190189A1 (ru) | 2018-07-05 | 2021-04-16 | Ханчжоу Дэк Биотек Ко., Лтд | Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты |
| JP2022500037A (ja) | 2018-09-14 | 2022-01-04 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための抗ｉｌ４受容体抗体 |
| IL282182B2 (en) | 2018-10-12 | 2025-09-01 | Hangzhou Dac Biotech Co Ltd | Cytotoxic drug conjugates with a bis linkage |
| US20210388053A1 (en) | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| EP3870601A4 (en) | 2018-10-25 | 2022-07-13 | Kindred Biosciences, Inc. | IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| CN120904316A (zh) | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
| CN113544153B (zh) | 2019-01-03 | 2024-12-10 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| CA3128264A1 (en) | 2019-01-31 | 2020-08-06 | Hangzhou Dac Biotech Co., Ltd | A conjugate of an amanita toxin with branched linkers |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| CN114040781A (zh) | 2019-06-24 | 2022-02-11 | 杭州多禧生物科技有限公司 | Tubulysin衍生物与细胞结合分子偶联物的制剂配方 |
| PH12021500050A1 (en) | 2019-06-24 | 2022-05-02 | Hangzhou Dac Biotech Co Ltd | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers |
| BR112022002771A2 (pt) | 2019-08-29 | 2022-08-09 | Kindred Biosciences Inc | Anticorpos anti-il31 para uso veterinário |
| AU2020400221A1 (en) | 2019-12-13 | 2022-05-19 | Harbour Biomed (Shanghai) Co., Ltd. | Anti-TSLP antibody and uses thereof |
| MX2022007676A (es) | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Anticuerpos caninizados biespecificos para tratar dermatitis atopica. |
| WO2021165417A1 (en) | 2020-02-19 | 2021-08-26 | Adivo Gmbh | Modified fc regions |
| MX2022011335A (es) | 2020-03-18 | 2022-10-07 | Kindred Biosciences Inc | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. |
| CN115996949A (zh) | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| KR20230005875A (ko) | 2020-04-22 | 2023-01-10 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학 용도를 위한 장시간-작용성 항-il31 항체 |
| EP4139344A4 (en) | 2020-04-22 | 2024-10-16 | Elanco US Inc. | Il4/il13 receptor molecules for veterinary use |
| BR112022025583A2 (pt) | 2020-06-19 | 2023-01-03 | Hangzhou Dac Biotech Co Ltd | Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos |
| KR20230038522A (ko) | 2020-07-10 | 2023-03-20 | 인베티엑스 인코포레이티드 | 고양이에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법 |
| GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
| US20230391878A1 (en) | 2020-09-01 | 2023-12-07 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
-
2017
- 2017-03-23 US US15/467,464 patent/US10093731B2/en active Active
- 2017-03-23 WO PCT/US2017/023788 patent/WO2018156180A1/en not_active Ceased
- 2017-12-15 US US15/844,142 patent/US10150810B2/en active Active
-
2018
- 2018-02-09 US US16/488,045 patent/US11673946B2/en active Active
- 2018-02-09 CN CN201880026436.4A patent/CN110769851B/zh active Active
- 2018-02-09 CA CA3053525A patent/CA3053525A1/en active Pending
- 2018-02-09 KR KR1020247015851A patent/KR102942127B1/ko active Active
- 2018-02-09 MA MA047609A patent/MA47609A/fr unknown
- 2018-02-09 AU AU2018224711A patent/AU2018224711B2/en active Active
- 2018-02-09 EP EP18756690.6A patent/EP3585429A4/en active Pending
- 2018-02-09 CN CN202311589839.9A patent/CN117603350A/zh active Pending
- 2018-02-09 JP JP2019545292A patent/JP7277370B2/ja active Active
- 2018-02-09 BR BR112019017308-0A patent/BR112019017308A2/pt active Search and Examination
- 2018-02-09 KR KR1020197025631A patent/KR20190127703A/ko not_active Ceased
- 2018-11-09 US US16/186,013 patent/US20190169285A1/en not_active Abandoned
-
2019
- 2019-08-21 MX MX2024012304A patent/MX2024012304A/es unknown
-
2020
- 2020-09-30 US US17/039,495 patent/US11697683B2/en active Active
-
2023
- 2023-05-03 US US18/311,777 patent/US12448438B2/en active Active
- 2023-05-08 JP JP2023076588A patent/JP7716441B2/ja active Active
- 2023-05-24 US US18/322,737 patent/US12435132B2/en active Active
-
2025
- 2025-02-19 AU AU2025201182A patent/AU2025201182A1/en active Pending
- 2025-05-27 JP JP2025087766A patent/JP2025138636A/ja active Pending
- 2025-09-10 US US19/325,042 patent/US20260092107A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511123A5 (https=) | ||
| JP7589269B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP7716441B2 (ja) | 獣医用抗ｉｌ－３１抗体 | |
| JP7303126B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| AU2018288803B2 (en) | Anti-BCMA heavy chain-only antibodies | |
| JP5771140B2 (ja) | 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤 | |
| JP2023524643A5 (https=) | ||
| JP2022545259A5 (https=) |